In this study, multiplex immunohistochemistry, drug testing of HR + /HER2- breast cancer organoids, single-cell sequencing, and primary cell coculture showed that the CDK4/6 inhibitor palbociclib promotes fibroblast senescence, thereby increasing IGF1 and FGF7 levels. Here, CDK4 is linked to breast cancer.